Physician profile
Joseph Daly
NPI 1164480174
$11,416.90
in general payments reported to CMS, 2019-2025
32 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $871 · 2021: $899 · 2022: $1,551 · 2023: $1,935 · 2024: $2,384 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,900 · Education: $45.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,899.62 |
| Education | $45.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,565.95 | 2019-2025 | Linzess, Skyrizi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,777.82 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $1,044.12 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $829.29 | 2019-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $630.20 | 2019-2025 | |
| Pfizer INC. | $553.19 | 2019-2025 | |
| Celgene Corporation | $360.32 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $329.83 | 2022-2025 | Dupixent |
| Genzyme Corporation | $322.79 | 2022-2025 | |
| Madrigal Pharmaceuticals | $304.25 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $179.36 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $172.48 | 2019-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $157.53 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $152.58 | 2019-2024 | Linzess |
| Lilly USA, LLC | $140.86 | 2024-2025 | Omvoh |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $138.90 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $135.06 | 2024-2025 | Zymfentra, Vegzelma |
| Ipsen Biopharmaceuticals, INC | $119.21 | 2025 | Iqirvo |
| Vivus LLC | $77.73 | 2019-2022 | |
| Allergan, INC. | $74.87 | 2019-2020 | |
| Lucid Diagnostics INC. | $69.51 | 2024 | |
| Nestle Healthcare Nutrition INC. | $61.34 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $42.52 | 2023 | Idacio |
| Merck Sharp & Dohme LLC | $39.30 | 2020 | |
| Braintree Laboratories, INC. | $32.66 | 2021-2023 | Sutab, Suflave |
| Eisai INC. | $18.85 | 2022 | |
| Shield Therapeutics INC | $18.70 | 2024 | |
| Covidien Lp | $15.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.08 | 2025 | Givlaari |
| Ferring Pharmaceuticals INC. | $12.34 | 2021 | |
| Ucb, INC. | $12.22 | 2020 | |
| Redhill Biopharma INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.